Jay P Ciezki

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA
    Urology 80:367-72. 2012
  2. doi request reprint American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer
    J P Ciezki
    Cleveland Clinic Foundation, Cleveland, OH, USA
    Clin Oncol (R Coll Radiol) 24:43-51. 2012
  3. ncbi request reprint Brachytherapy or surgery? A composite view
    Jay P Ciezki
    Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Oncology (Williston Park) 23:960-4. 2009
  4. ncbi request reprint PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 64:512-7. 2006
  5. ncbi request reprint Prostate brachytherapy for localized prostate cancer
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Curr Treat Options Oncol 6:389-93. 2005
  6. ncbi request reprint A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy
    Jay P Ciezki
    Department of Radiation Oncology, The Glickman Urological Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 60:1347-50. 2004
  7. doi request reprint The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 75:467-71. 2010
  8. doi request reprint Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer
    Rahul D Tendulkar
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Int J Radiat Oncol Biol Phys 87:94-9. 2013
  9. ncbi request reprint Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
  10. doi request reprint Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44113, USA
    Int J Radiat Oncol Biol Phys 73:1439-45. 2009

Detail Information

Publications31

  1. doi request reprint Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA
    Urology 80:367-72. 2012
    ..To account for lead-time bias, we compared the 10-year metastasis-free survival rate for the prescreening era group (PRE) to the 15-year metastases-free survival rate of the postscreening era group (POST)...
  2. doi request reprint American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer
    J P Ciezki
    Cleveland Clinic Foundation, Cleveland, OH, USA
    Clin Oncol (R Coll Radiol) 24:43-51. 2012
    ....
  3. ncbi request reprint Brachytherapy or surgery? A composite view
    Jay P Ciezki
    Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Oncology (Williston Park) 23:960-4. 2009
    ..This review will focus the comparison on toxicity, the "soft" endpoints of biochemical relapse-free survival and clinical relapse-free survival, and the "hard" endpoint of prostate cancer-specific mortality...
  4. ncbi request reprint PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 64:512-7. 2006
    ..To analyze prostate-specific antigen (PSA) kinetics in patients treated with prostate brachytherapy (PI) with a minimum of 5 years of PSA follow-up...
  5. ncbi request reprint Prostate brachytherapy for localized prostate cancer
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Curr Treat Options Oncol 6:389-93. 2005
    ..Adopting this evidence-based algorithm has led to the increased application of PI...
  6. ncbi request reprint A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy
    Jay P Ciezki
    Department of Radiation Oncology, The Glickman Urological Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 60:1347-50. 2004
    ....
  7. doi request reprint The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 75:467-71. 2010
    ..To assess the relationship between prostate-specific antigen (PSA) testing frequency and biochemical failure (bF) and clinical failure (cF)...
  8. doi request reprint Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer
    Rahul D Tendulkar
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Int J Radiat Oncol Biol Phys 87:94-9. 2013
    ..We aim to identify the causes of death and factors predictive for mortality in this population...
  9. ncbi request reprint Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
    ..To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival...
  10. doi request reprint Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44113, USA
    Int J Radiat Oncol Biol Phys 73:1439-45. 2009
    ..Most of the present data regarding the PG of GS7 CaP refer to surgical specimens. Our goal was to determine whether the biopsy GS used at the time of medical decision making predicted for the biochemical outcome...
  11. ncbi request reprint PSA bounce predicts early success in patients with permanent iodine-125 prostate implant
    Chandrika Patel
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 63:110-3. 2004
    ....
  12. ncbi request reprint Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate
    Aimee L Quan
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 68:1237-41. 2006
    ..To analyze whether prostate size affects biochemical relapse-free survival (bRFS)...
  13. doi request reprint Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy
    Rahul D Tendulkar
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Int J Radiat Oncol Biol Phys 82:1397-404. 2012
    ..Modern outcomes of high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) for high-risk (HR) prostate cancer are not well described...
  14. ncbi request reprint Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study
    Mohamed A Elshaikh
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 62:164-9. 2005
    ..To evaluate the effectiveness of prophylactic tamsulosin (Flomax) in reducing the urinary symptoms in patients undergoing 125I prostate implantation (PI) for prostate adenocarcinoma...
  15. ncbi request reprint Aggressiveness of familial prostate cancer
    Patrick A Kupelian
    Glickman Urological Institute and Radiation Oncology Department, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 24:3445-50. 2006
    ..To report on the aggressiveness of sporadic versus familial prostate cancer...
  16. doi request reprint Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation
    Andrew D Vassil
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    Urology 76:1251-7. 2010
    ....
  17. ncbi request reprint Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY, USA
    Radiother Oncol 71:29-33. 2004
    ....
  18. ncbi request reprint Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer
    Christopher J Weight
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 65:347-50. 2006
    ..To determine if the presence of perineural invasion (PNI) predicts biochemical recurrence in patients who underwent low-dose-rate brachytherapy for the treatment of localized prostate cancer...
  19. ncbi request reprint Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer
    Patrick A Kupelian
    Department of Radiation Oncology, M D Anderson Cancer Center Orlando, Orlando, FL 32806, USA
    Int J Radiat Oncol Biol Phys 58:25-33. 2004
    ....
  20. doi request reprint ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer
    May Abdel-Wahab
    Cleveland Clinic Foundation, Taussig Comprehensive Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Radiol 9:233-8. 2012
    ..In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment...
  21. doi request reprint American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer
    Steven J Frank
    Department of Radiation Oncology, M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Brachytherapy 10:357-62. 2011
    ..The purpose of this review was to provide clarification on the appropriateness criteria and management considerations for the treatment of prostate cancer with permanent prostate brachytherapy...
  22. ncbi request reprint Comparison of biochemical failure definitions for permanent prostate brachytherapy
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1487-93. 2006
    ..To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy...
  23. pmc Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer
    Grant K Hunter
    Cleveland Clinic Department of Radiation Oncology, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Prostate Cancer 2012:853487. 2012
    ..The presence of DM at the time of treatment was significantly associated with worse late GI and GU toxicity. RT was significantly associated with worse late GI toxicity compared to PI and RP...
  24. doi request reprint Association of body mass index with prostate cancer biochemical failure
    David Ly
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
    J Urol 183:2193-9. 2010
    ..We determined whether there is an association between body mass index and biochemical failure in men treated for low and intermediate risk prostate cancer with various treatment modalities...
  25. ncbi request reprint Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy
    Mohamed A Elshaikh
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 61:152-5. 2003
    ..To correlate anatomic, procedural, and dosimetric parameters with the rate of intermittent self-catheterization (ISC)...
  26. doi request reprint Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels
    Andrew J Stephenson
    Section of Urologic Oncology, Glickman Urological and Kidney Institute, Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195 0001, USA corrected
    Eur Urol 55:610-6. 2009
    ..5 ng/ml) given the 17% prostate cancer (pCA) detection rate at PSA of 1.1-2.0. The outcome of patients treated at PSA < or = 2.5 is poorly defined, and advantages associated with such an early diagnosis are uncertain...
  27. doi request reprint Outcomes after photoselective vaporization of the prostate and transurethral resection of the prostate in patients who develop prostatic obstruction after radiation therapy
    Benjamin Abelson
    Cleveland Clinic Lerner College of Medicine, Cleveland, OH
    Urology 83:422-7. 2014
    ....
  28. ncbi request reprint Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer
    David J Adelstein
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, OH 44195, USA
    Lung Cancer 36:167-74. 2002
    ..Patients downstaged to mediastinal node negativity have a prognosis similar to those with de novo stage I(B) and II disease. Distant metastases are the major cause of treatment failure...
  29. doi request reprint Future directions from past experience: a century of prostate radiotherapy
    Matthew C Ward
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH Electronic address
    Clin Genitourin Cancer 12:13-20. 2014
    ..This article represents a complete description of the evolution of prostate cancer radiation therapy with the goal of illuminating the historical basis for current challenges facing oncologists and their patients. ..
  30. doi request reprint The current status of image-guided external beam radiotherapy for prostate cancer
    Kevin L Stephans
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Urol 20:223-8. 2010
    ..To assess the current status and technological advances in image-guided external beam radiotherapy for prostate cancer...
  31. ncbi request reprint Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007
    ..To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group...